CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 223 enrolled
Drug / intervention
IV meloxicam +1 moredrug
Likely dose
IV meloxicam 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05291598
NCT05291598Phase 3Completed
CompareCT.gov

IV Meloxicam for Pain Management Post TJA: Prospective Randomized Trial

University of Miami·interventional·Posted Mar 22, 2022·Updated Aug 14, 2024

In Brief

A Phase 3 clinical trial evaluating IV meloxicam and Ketorolac for Total Knee Replacement and Total Hip Replacement. Completed, enrolled 223 participants across 1 site.

Detailed Summary

The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee and hip arthroplasty could be observed with the substitution of Intravenous meloxicam for ketorolac in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTotal Knee Replacement, Total Hip Replacement
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedMar 22, 2022
Enrollment StartMay 1, 2022
Primary CompletionMay 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 4.3 years ago

Interventions

IV meloxicamdrug

Participants will be administered meloxicam 30 mg IV push pre-operatively.

Ketorolacdrug

Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.